Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from RTTNews

15:56 EDT 23rd June 2018 | BioPortfolio

Here are the most relevant search results for "RTTNews" found in our extensive news archives from over 250 global news sources.

More Information about RTTNews on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about RTTNews for you to read. Along with our medical data and news we also list RTTNews Clinical Trials, which are updated daily. BioPortfolio also has a large database of RTTNews Companies for you to search.

Showing News Articles 1–25 of 415 from RTTNews

Friday 22nd June 2018

An Ear To The Pharma: 15 Stocks To Watch (AKAO, PTIE, ASNS.)

Only a week left in the quarter, and the week that passed by saw some of the DMD drug stocks make headlines. Now, here are some of the pharma/biotech stocks and upcoming events to keep an ear out for in the coming week.

Thursday 21st June 2018

XBIO Turns Heads, HRTX Hits New High, RYTM In Good Rhythm, SBOT On Watch

The following are some of the stocks that gained the largest percentage in price today in the pharma/biotech sector.

In The Spotlight: Sangamo Therapeutics

Shares of Sangamo Therapeutics Inc. (SGMO) are down nearly 33% from their 52-week high to $18. Given the fact that the Company has potential clinical data readouts from 7 studies beginning in late summer of this year to 2019, it is worth keeping an eye on this stock.

It's Raining IPOs Today, ATOS To Report Data In Q3, KIN Well-Funded, STAA Shines

Today's Daily Dose brings you news about Atossa's progress in phase I study of its proprietary topical Endoxifen in men; the three biopharmaceutical companies that are set to debut on the Nasdaq on June 21, 2018; Kindred Biosciences' financial position; FDA panel review date of Paratek's Omadacycline NDA, and STAAR Surgical's resolution of FDA warning letter.

Wednesday 20th June 2018

NEPT Hits A High, CLBS Up 118% In 2 Days, APEN Abuzz, Busy Days Ahead For TSRO

The following are some of today's top gainers in the pharma/biotech sector.

ANIK Plunges On Disappointing Data, MRNS Initiates Marigold, SSKN On Watch

Today's Daily Dose brings you news about Alexion's progress in paroxysmal nocturnal hemoglobinuria; Anika's disappointing results of CINGAL in osteoarthritis of the knee; timeline of Kala's submission of New Drug Application for KPI-121 0.25% for the treatment of dry eye disease; Marinus' Marigold study and Pacira's deal with China-based Nuance Biotech.

Tuesday 19th June 2018

CLBS Firing On All Cylinders, SLDB Gets Ignited, SRPT Walks The Talk, SRRK Rocks

The following are some of today's top gainers in the pharma/biotech sector.

Alexion Submits BLA For Priority Review And Approval Of ALXN1210

Alexion Pharmaceuticals, Inc. (ALXN) submitted on Tuesday a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the Company's investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

New Drugs Approved In May

The bench to bedside journey of drugs is no easy task. Some drug candidates fail to complete the journey while many make it to the finish line only after undergoing numerous obstacles.

CSBR Up 36% This Month, ZIOP Hit By Clinical Hold, Watch Out For SRPT Today

Today's Daily Dose brings you news about Royalty Pharma's investment in Biohaven Pharma; Champions Oncology's partnership with NSABP Foundation and Puma Biotechnology; upcoming regulatory catalyst of Myriad Genetics; Valeant Pharma's plaque psoriasis setback; Sarepta's presentation to watch out for the day, and FDA hold on Ziopharm's phase I trial of CD19-targeted CAR T therapy.

Monday 18th June 2018

VSTM Turns Heads, PTCT On Fire, CBPO Gets A Suitor, TPIV Up 134% This Month

The following are some of today's top gainers in the pharma/biotech sector.

Valeant Suffers Psoriasis Setback

Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.

Johnson & Johnson Vision: FDA Approves IDESIGN Refractive Studio - Quick Facts

Johnson & Johnson Vision, a unit of Johnson & Johnson (JNJ), said that the U.S. Food and Drug Administration (FDA) has approved of the iDESIGN Refractive Studio, making it the only system to use topography-integrated, wavefront-guided technology.

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ObsEva SA's (OBSV) phase 2b clinical trial of Linzagolix for the treatment of endometriosis-associated pain has achieved primary and secondary endpoints.

What Awaits ObsEva - Pain Or Gain?

There is every reason to keep an eye on Obseva SA (OBSV), a specialty biopharmaceutical company operating in the field of women's health and reproductive medicine, today.

Saturday 16th June 2018

An Ear To The Pharma: 5 Stocks To Watch (OBSV, GERN, SRPT.)

The week that went by saw NASH drug stocks back in focus as positive results from a phase II study of Galmed Pharmaceuticals Ltd.'s (GLMD) investigational drug Aramchol seems to have had a positive rub off impact. Aramchol is being developed for treatment of patients with biopsy proven non-alcoholic steatohepatitis, or NASH.

Friday 15th June 2018

Teva To Discontinue Clinical Trial Of Fremanezumab For Chronic Cluster Headache

Israeli generic medicines producer Teva Pharmaceutical Industries (TEVA) announced Friday that it will discontinue the trial of fremanezumab for use in chronic cluster headache, which is part of the larger ENFORCE Phase III clinical development program.

Thursday 14th June 2018

FLGT Abuzz, INSY Breathes Easy, NITE Sparkles

The following are some of today's top gainers in the pharma/biotech sector.

This Day That Year: Athenex

Shares of Athenex Inc. (ATNX) have returned nearly 46% over the last 1 year while the iShares NASDAQ Biotechnology Index (ETF) has gained a mere 12% during the same period.

Wednesday 13th June 2018

GALT Vaults As NASH Research Sparks Interest, MDGL Abuzz, MACK Awaits Data

The following are some of today's top gainers in the pharma/biotech sector.

Allergan Reports Positive Topline Phase 3 Clinical Data For Bimatoprost SR

Allergan plc (AGN) announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure or IOP in patients with open-angle glaucoma or ocular hypertension.

CAH Closer To FDA Approval, Another Alzheimer's Disease Drug Fails, VTVT Tanks

Today's Daily Dose brings you news about expanded FDA approval for Agilent's Dako PD-L1 IHC 22C3 pharmDx assay; Albireo Pharma's lead product candidate A4250 securing rare pediatric disease designation from the FDA for the treatment of progressive familial intrahepatic cholestasis; Cardinal Health's INCRAFTAAA Stent Graft System getting favorable FDA panel recommendation, among others.

Tuesday 12th June 2018

GLMD Arrests Investor Attention, SAGE Excited, GEMP On Close Watch

The following are some of today's top gainers in the pharma/biotech sector.

Patience Pays Off For Galmed Investors...

Shares of Galmed Pharmaceuticals Ltd. (GLMD) skyrocketed as much as 284% in early trade on Tuesday, and as of this writing are up over 180%, following encouraging top-line, 52-week results from its study dubbed ARREST.

Monday 11th June 2018

EOLS Recovers, BLCM Awaits DATA, Time To Keep An Eye On RARX

The following are some of today's top gainers in the pharma/biotech sector.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks